Table 2.
Risk factors for decreased kidney function among all patients and eGFR groups.
| Risk Factors for Decreased Kidney Function | Odds Ratio | 95% CI | P |
|---|---|---|---|
| Univariate regression (n = 1420) | |||
| Diagnosis (n = 1420) | - | - | 0.0065 |
| ET vs. MF (n = 942) | 0.674 | 0.525–0.867 | 0.0021 |
| ET vs. PV (n = 1024) | 0.926 | 0.730–1.174 | 0.5243 |
| MF vs. PV (n = 874) | 1.372 | 1.060–1.777 | 0.0160 |
| JAK2V617F mutation (yes vs. no; n = 1315) | 1.244 | 0.981–1.576 | 0.0711 |
| eGFR2 vs. eGFR1 (n = 1030) | 1.033 | 0.764–1.395 | 0.8347 |
| eGFR3 vs. eGFR1 (n = 576) | 1.435 | 0.982–2.097 | 0.0619 |
| eGFR3 vs. eGFR2 (n = 1024) | 1.390 | 1.005–1.922 | 0.0464 |
| Diabetes mellitus (yes vs. no; n = 1251) | 1.815 | 1.215–2.711 | 0.0036 |
| eGFR2 vs. eGFR1 (n = 976) | 0.663 | 0.382–1.153 | 0.1454 |
| eGFR3 vs. eGFR1 (n = 542) | 1.878 | 1.071–3.295 | 0.0279 |
| eGFR3 vs. eGFR2 (n = 984) | 2.830 | 1.763–4.543 | <0.0001 |
| Arterial hypertension (yes vs. no; n = 956) | 2.419 | 1.879–3.114 | <0.0001 |
| eGFR2 vs. eGFR1 (n = 739) | 1.405 | 1.016–1.943 | 0.0399 |
| eGFR3 vs. eGFR1 (n = 436) | 3.983 | 2.671–5.939 | <0.0001 |
| eGFR3 vs. eGFR2 (n = 737) | 2.836 | 2.023–3.976 | <0.0001 |
| Hyperlipidemia (yes vs. no; n = 181) | 3.570 | 1.445–8.819 | 0.0058 |
| eGFR2 vs. eGFR1 (n = 152) | 1.815 | 0.477–6.905 | 0.3820 |
| eGFR3 vs. eGFR1 (n = 81) | 6.220 | 1.501–25.779 | 0.0118 |
| eGFR3 vs. eGFR2 (n = 129) | 3.429 | 1.207–9.739 | 0.0207 |
| Leukocytes (>8.4 vs. ≤8.4 G/L; n = 1408) | 1.367 | 1.116–1.675 | 0.0025 |
| eGFR2 vs. eGFR1 (n = 1093) | 1.023 | 0.785–1.333 | 0.8670 |
| eGFR3 vs. eGFR1 (n = 619) | 1.624 | 1.181–2.231 | 0.0028 |
| eGFR3 vs. eGFR2 (n = 1104) | 1.587 | 1.218–2.067 | 0.0006 |
| Platelets (>492 vs. ≤492 G/L; n = 1395) | 0.832 | 0.679–1.019 | 0.0755 |
| eGFR2 vs. eGFR1 (n = 1080) | 1.078 | 0.827–1.406 | 0.5774 |
| eGFR3 vs. eGFR1 (n = 618) | 0.755 | 0.550–1.036 | 0.0814 |
| eGFR3 vs. eGFR2 (n = 1092) | 0.700 | 0.538–0.911 | 0.0079 |
| Uric acid (>5.7 vs. ≤5.7 mg/dL; n = 1012) | 2.548 | 1.986–3.268 | <0.0001 |
| eGFR2 vs. eGFR1 (n = 790) | 1.587 | 1.150–2.192 | 0.0050 |
| eGFR3 vs. eGFR1 (n = 444) | 4.351 | 2.923–6.476 | <0.0001 |
| eGFR3 vs. eGFR2 (n = 790) | 2.741 | 1.971–3.811 | <0.0001 |
| Absolute neutrophil count (>5.48 vs. ≤5.48 G/L; n = 1254) | 1.397 | 1.126–1.734 | 0.0024 |
| eGFR2 vs. eGFR1 (n = 981) | 1.077 | 0.814–1.426 | 0.6019 |
| eGFR3 vs. eGFR1 (n = 545) | 1.690 | 1.204–2.373 | 0.0024 |
| eGFR3 vs. eGFR2 (n = 982) | 1.569 | 1.183–2.081 | 0.0018 |
| Absolute monocyte count (>0.55 vs. ≤0.55 G/L; n = 1312) | 1.349 | 1.094–1.664 | 0.0052 |
| eGFR2 vs. eGFR1 (n = 1018) | 0.972 | 0.739–1.278 | 0.8382 |
| eGFR3 vs. eGFR1 (n = 579) | 1.589 | 1.144–2.207 | 0.0058 |
| eGFR3 vs. eGFR2 (n = 1027) | 1.635 | 1.243–2.150 | 0.0004 |
| LDH (>267.5 vs. ≤267.5 U/L; n = 1356) | 1.533 | 1.245–1.887 | <0.0001 |
| eGFR2 vs. eGFR1 (n = 1056) | 1.197 | 0.913–1.570 | 0.1940 |
| eGFR3 vs. eGFR1 (n = 592) | 1.949 | 1.405–2.703 | <0.0001 |
| eGFR3 vs. eGFR2 (n = 1064) | 1.628 | 1.241–2.136 | 0.0004 |
| CRP (>1.4 vs. ≤1.4 mg/L; n = 356) | 1.633 | 1.091–2.444 | 0.0172 |
| eGFR2 vs. eGFR1 (n = 273) | 0.980 | 0.579–1.660 | 0.9411 |
| eGFR3 vs. eGFR1 (n = 162) | 2.109 | 1.125–3.953 | 0.0200 |
| eGFR3 vs. eGFR2 (n = 277) | 2.151 | 1.269–3.645 | 0.0044 |
| MPN duration (>42 vs. ≤42 months; n = 1183) | 1.507 | 1.207–1.882 | 0.0003 |
| eGFR2 vs. eGFR1 (n = 904) | 1.482 | 1.101–1.996 | 0.0095 |
| eGFR3 vs. eGFR1 (n = 523) | 1.913 | 1.350–2.710 | 0.0003 |
| eGFR3 vs. eGFR2 (n = 939) | 1.290 | 0.973–1.710 | 0.0764 |
| MPN therapy (yes vs. WW; n = 1215) * | 1.784 | 1.428–2.230 | <0.0001 |
| eGFR2 vs. eGFR1 (n = 941) | 1.267 | 0.952–1.686 | 0.1049 |
| eGFR3 vs. eGFR1 (n = 535) | 2.514 | 1.762–3.587 | <0.0001 |
| eGFR3 vs. eGFR2 (n = 939) | 1.985 | 1.470–2.679 | <0.0001 |
| HU-treated (yes vs. WW; n = 780) | 1.734 | 1.286–2.338 | 0.0003 |
| eGFR2 vs. eGFR1 (n = 639) | 1.639 | 1.099–2.444 | 0.0153 |
| eGFR3 vs. eGFR1 (n = 316) | 2.421 | 1.493–3.926 | 0.0003 |
| eGFR3 vs. eGFR2 (n = 605) | 1.477 | 1.004–2.172 | 0.0475 |
| RUX-treated (yes vs. WW; n = 618) | 2.412 | 1.560–3.728 | <0.0001 |
| eGFR2 vs. eGFR1 (n = 506) | 1.517 | 0.810–2.842 | 0.1928 |
| eGFR3 vs. eGFR1 (n = 260) | 3.663 | 1.839–7.294 | 0.0002 |
| eGFR3 vs. eGFR2 (n = 470) | 2.413 | 1.446–4.027 | 0.0007 |
| Other MPN treatment (yes vs. WW; n = 865) | 1.737 | 1.331–2.267 | <0.0001 |
| eGFR2 vs. eGFR1 (n = 682) | 1.006 | 0.714–1.417 | 0.9734 |
| eGFR3 vs. eGFR1 (n = 389) | 2.344 | 1.557–3.527 | <0.0001 |
| eGFR3 vs. eGFR2 (n = 659) | 2.330 | 1.647–3.297 | <0.0001 |
| Antithrombotic therapy (yes vs. no; n = 1251) | 1.196 | 0.946–1.511 | 0.1348 |
| eGFR2 vs. eGFR1 (n = 967) | 1.296 | 0.958–1.752 | 0.0925 |
| eGFR3 vs. eGFR1 (n = 548) | 1.318 | 0.918–1.892 | 0.1314 |
| eGFR3 vs. eGFR2 (n = 939) | 1.017 | 0.750–1.380 | 0.9113 |
| Multiple Regression | |||
| eGFR2 vs. eGFR1 (n = 639) * | - | - | - |
| HU-treated (yes vs. WW) | 1.639 | 1.099–2.444 | 0.0153 |
| eGFR3 vs. eGFR1 (n = 278) †,‡ | - | - | - |
| Arterial hypertension (yes vs. no) | 3.073 | 1.746–5.405 | <0.0001 |
| Uric acid (>5.7 vs. ≤ 5.7 mg/dL) | 4.918 | 2.787–8.677 | <0.0001 |
| HU-treated (yes vs. WW) | 3.509 | 1.630–7.557 | 0.0013 |
| RUX-treated (yes vs. WW) | 5.416 | 1.927–15.223 | 0.0014 |
| Other MPN treatment (yes vs. WW) | 2.477 | 1.277–4.803 | 0.0073 |
| eGFR3 vs. eGFR2 (n = 589) § | - | - | - |
| Arterial hypertension (yes vs. no) | 2.004 | 1.440–2.789 | <0.0001 |
| Uric acid (>5.7 vs. ≤5.7 mg/dL) | 2.254 | 1.617–3.140 | <0.0001 |
| LDH (>267.5 vs. ≤267.5 U/L) | 1.448 | 1.036–2.023 | 0.0301 |
| HU-treated (yes vs. WW) | 1.797 | 1.162–2.780 | 0.0085 |
| Other MPN treatment (yes vs. WW) | 1.645 | 1.095–2.471 | 0.0165 |
* Initial model for eGFR2 vs. eGFR1: arterial hypertension, uric acid, MPN duration, and HU-treated. † Initial model for eGFR3 vs. eGFR1: diabetes mellitus, arterial hypertension, leukocytes, and uric acid; neutrophils, monocytes, LDH, CRP, MPN duration, HU-treated, RUX-treated, and other MPN treatment. ‡ Hyperlipidemia (n = 69) was not assessed in multiple regression analysis because of the low number of patients. § Initial model for eGFR3 vs. eGFR2: JAK2V617F mutation, diabetes mellitus, arterial hypertension, leukocytes, platelets, and uric acid; neutrophils, monocytes, LDH, CRP, HU-treated, RUX-treated, and other MPN treatment. Bolded values indicate significant odds ratios and significant p values.